iRhythm announces results of multiple new studies at ACC.23/WCC

iRhythm Technologies recently presented the results of multiple new studies at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology, ACC.23/WCC. The CAMELOT study, titled "Comparative Effectiveness Of Ambulatory Monitors For Arrhythmia Diagnosis: A Retrospective Analysis Of Medicare Beneficiaries," demonstrated that: Long-term continuous monitoring with Zio XT is associated with the highest diagnostic yield and the fastest time to clinical diagnosis compared to all other ambulatory cardiac monitors when looking at specified arrhythmias. Zio XT has the lowest likelihood of retesting compared to all other ACMs. Zio XT is associated with the lowest acute care healthcare resource utilization compared to all other ACMs. The principal finding is that Zio XT, prescribed for up to 14 days of monitoring, is associated with the highest diagnostic yield and fastest time to diagnosis, lowest odds of 180-day retesting, and the lowest risk of emergency department and inpatient hospitalization compared to Holter, MCT, ambulatory event monitors, and other LTCM services. The presented findings demonstrated that all other monitoring services had an odds of clinical arrhythmia diagnosis that was 20%-50% less than Zio XT after controlling for other variables. All other monitoring services also had 1.4 to 5.7 greater odds of subsequent retesting compared to Zio XT. Outside of CAMELOT, other notable studies were presented at ACC.23/WCC. The Zio monitor post-approval extended wear study, titled "Initial Real World And Clinical Experience Of The Next Generation Ambulatory ECG Zio Monitor: Implications For Standard And Extended Wear Monitoring," compared Zio XT with the next generation Zio monitor. It found the Zio monitor demonstrated even higher compliance, higher ECG analyzable time, increased wear time and improved signal quality than Zio XT. The results of the VT prognostic value study, titled "Prevalence And Prognostic Value Of Ventricular Tachycardia On Ambulatory ECG Monitoring," found that non-sustained ventricular tachycardia was independently associated with increased mortality, and may act as a proxy biomarker for cardiovascular risk.